VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

SKYE Stock  USD 2.66  0.04  1.48%   
About 61% of Skye Bioscience,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Skye Bioscience, Common suggests that many traders are alarmed. The current market sentiment, together with Skye Bioscience,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Skye Bioscience, Common stock news signals to limit their universe of possible portfolio assets.
  
VBI Vaccines Inc. , a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of diseas

Read at businesswire.com
businesswire News
  

Skye Bioscience, Fundamental Analysis

We analyze Skye Bioscience,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Target Price

Target Price Comparative Analysis

Skye Bioscience, is currently under evaluation in target price category among its peers.

Skye Bioscience, Common Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Skye Bioscience, stock to make a market-neutral strategy. Peer analysis of Skye Bioscience, could also be used in its relative valuation, which is a method of valuing Skye Bioscience, by comparing valuation metrics with similar companies.

Peers

Skye Bioscience, Related Equities

CABACabaletta Bio   12.76   
0%
100.0%
TNXPTonix Pharmaceuticals   4.35   
0%
34.0%
LRMRLarimar Therapeutics   2.77   
0%
21.0%
ALECAlector   1.79   
0%
14.0%
PASGPassage Bio   1.69   
0%
13.0%
VXRTVaxart   1.37   
0%
10.0%
RVMDRevolution Medicines   0.98   
0%
7.0%
BDTXBlack Diamond   0.45   
3.0%
0%
SILOSilo Pharma   1.01   
7.0%
0%
STOKStoke Therapeutics   1.06   
8.0%
0%
JAGXJaguar Animal   1.16   
9.0%
0%
GLUEMonte Rosa   1.74   
13.0%
0%

Complementary Tools for Skye Stock analysis

When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets